Pharmaceutical & Diagnostic Innovation

, Volume 4, Issue 3, pp 14–16 | Cite as

Improving Treatment of Early Breast Cancer

Recent Developments in Molecular Prognostics
Emerging Technology

Executive summary

The January 2006 announcement that Medicare in California would reimburse the Oncotype DX™ gene-expression test for predicting clinical outcome and response to adjuvant therapy in patients with early breast cancer has focused attention on molecular prognostics for this disease. The fundamental drivers for development of this novel technology class are the size of the patient population, and the limitations of current clinical tools for predicting patient outcome and the risk/benefit of adjuvant treatment.

Only two molecular prognostic tests are currently marketed, Oncotype DX™ from Genomic Health and MammaPrint® from the Dutch company Agendia, both of which became commercially available only within the last 2 years. However, experimental gene-expression tests are undergoing clinical evaluation and research with Veridex, Ipsogen and the Centre for Genetic Engineering and Biotechnology in Cuba. Although this subclass of molecular diagnostics is still at early stages of...


Breast Cancer Tamoxifen Early Breast Cancer Recurrence Score Molecular Diagnostics 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    American Cancer Society. Cancer facts and figures 2006. Atlanta (GA): American Cancer Society, 2006Google Scholar
  2. 2.
    Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351 (27): 2817–26PubMedCrossRefGoogle Scholar
  3. 3.
    van’t Veer LJ, Dai H, van der Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415 (6871): 530–6CrossRefGoogle Scholar
  4. 4.
    van der Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347 (25): 1999–2009PubMedCrossRefGoogle Scholar
  5. 5.
    Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365 (9460): 671–9PubMedGoogle Scholar
  6. 6.
    Foekens AJ, Atkins D, Zhang, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol. Epub 2006 Feb 27Google Scholar
  7. 7.
    Jacquemier J, Ginestier C, Rougement J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res. 2005; 65 (3): 767–79PubMedGoogle Scholar
  8. 8.
    Besada V, Diaz M, Becker M, et al. Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance. Proteomics 2006; 6 (3): 1038–48PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Personalised recommendations